Quantum BioPharma (NASDAQ: QNTM) Picks Up Buy Rating and $8 Price Target as Phase 2 MS Trial Nears - Quan
Quantum BioPharma (QNTM) received a Buy rating and $8 price target from Rodman & Renshaw, more than double its current share price. The rating is based on LUCID-MS, an experimental oral therapy for progressive multiple sclerosis, which targets the PAD2 enzyme. The FDA cleared the drug for a Phase 2 trial, with enrollment expected to begin in 2027 and results projected for 2029. The company has $9.5 million in cash but may need to raise additional capital for the trial. Quantum also holds a 19.5%
How this was made
The 30-second read
Why it matters
Analyst coverage could attract new investors, but the company's need for further financing and trial risk remain significant.
Market read
New coverage may spark short-term price movement, but long-term upside hinges on Phase 2 trial outcomes and financing.
What to watch
Potential need for additional capital before Phase 2 results could pressure the stock.
Background
Quantum BioPharma is a clinical-stage biotech developing an oral PAD2 inhibitor for progressive multiple sclerosis.
Ticker impact
Rodman & Renshaw initiated coverage with a Buy rating and an $8 price target, up from the recent $3 trading range.
Potential upside of 150%+ if market re-rates near the $8 target.
Coverage is new and the target is more than double current price; however, the catalyst is an analyst opinion, not a material corporate event.
Market effects
Highlights potential for novel MS therapies, may boost biotech sector sentiment.
Limited to US biotech investors; no broader regional effect.
Modest, as MS market is global but the news is US-focused.
Counterpoint
The $8 target may be overly optimistic given early-stage trial risk and upcoming dilution.
Key entities
- companyQuantum BioPharma Ltd.
Developer of LUCID-MS, an oral therapy for progressive MS.
- analyst_firmRodman & Renshaw
Investment bank that initiated coverage with a Buy rating and $8 price target.
